An expert discusses how recent clinical advancements and biomarker-driven strategies are reshaping first-line treatment decisions in metastatic triple-negative breast cancer (mTNBC), emphasizing the ...

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and ...

During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

Nicole A. Cipriani, MD, offers guidance for community oncologists regarding the role of BRAF p.V600E testing in patients with papillary thyroid carcinoma.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.